AMAG Pharmaceuticals Investors File Securities Class Action Lawsuit Against AMAG Pharmaceuticals Over Feraheme
A securities class action lawsuit was filed against AMAG Pharmaceuticals in the U.S. District Court for the District of Massachusetts on behalf of purchasers of AMAG Pharmaceuticals common stock (AMAG) in the secondary public offering on or about January 21, 2010, for alleged violations of the federal securities laws, according to a class action press release.
The AMAG Pharmaceuticals securities class action complaint reportedly alleges, among other things, that the AMAG Pharmaceuticals Registration Statement with respect to the secondary public offering on or about January 21, 2010 failed to disclose that users of AMAG Pharmaceuticals primary drug, Feraheme, had suffered adverse reactions, some requiring hospitalization.
If You Have Thoughts On The AMAG Pharmaceuticals Securities Class Action Lawsuit, Share Your Class Action Comments Below.